AstraZeneca India touches roof on launching ‘FORXIGA’ for treatment of Type 2 diabetes

11 Jun 2015 Evaluate

AstraZeneca Pharma India is locked at upper circuit limit of Rs. 1147.70, up by 191.25 points or 20.00% from its previous closing of Rs. 956.45 on the BSE.

The scrip opened at Rs. 962.10 and has touched a high and low of Rs. 1147.70 and Rs. 958.00 respectively. So far 1,44,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 1245.00 on 23-Jun-2014 and a 52 week low of Rs. 785.30 on 17-Dec-2014.

Last one week high and low of the scrip stood at Rs. 1147.70 and Rs. 895.10 respectively. The current market cap of the company is Rs. 2,869.00 crore.

The promoters holding in the company stood at 75.00% while Institutions and Non-Institutions held 15.69% and 9.31% respectively.

AstraZeneca Pharma India, a leading biopharmaceutical company, has launched FORXIGA (dapaglifozin), a breakthrough treatment for Type 2 diabetes mellitus. It is available in the markets from May 2015.

FORXIGA belongs to a new class of Type 2 diabetes mellitus medication-a highly selective inhibitor of sodium-glucose cotransporter 2 (SGLT2). It has an unique insulin independent mode of action that helps remove excess glucose from the body via urine which is associated with reductions in glycated haemoglobin (HbA1c), weight and systolic blood pressure. Globally, FORXIGA is the first medicine in the new SGLT2 inhibitor class to gain regulatory approval for the treatment of Type 2 diabetes mellitus.

FORXIGA tablets are indicated as a once-daily oral medication to improve glycaemic control in adult patients with Type 2 diabetes mellitus. FORXIGA is indicated to be used as an adjunct to diet and exercise in combination with other glucose-lowering medicinal products, including insulin, or as a monotherapy in metformin-intolerant patients.

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.


Astrazeneca Pharma I Share Price

8001.40 -60.50 (-0.75%)
09-Apr-2025 09:42 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1671.65
Dr. Reddys Lab 1085.25
Cipla 1410.70
Lupin 1935.25
Zydus Lifesciences 839.35
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...